{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-26-003126","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2026-05-14T20:18:53+00:00","discovered_at":"2026-05-14T20:20:00.231943+00:00","generated_at":"2026-05-14T20:46:38.860348+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VolitionRx Q1 2026 revenue $1.0M; $5M milestone potential from feline lymphoma test","bullets":["Revenue of $1.0M in Q1 2026 vs $0.2M in Q1 2025; operating loss decreased 3% YoY.","Net cash used in operations was $5.3M; raised $5.4M from ATM equity and $1.9M from convertible note.","Received $1M in non-dilutive Walloon Region funding; ~$0.9M more expected over 12 months.","Feline lymphoma assay manuscript submitted for peer review; expected to unlock $5M milestone payment.","Discussions ongoing with >12 diagnostic companies for licensing; Nu.Q Lung Cancer reimbursement in France progressing."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-003126","json":"https://secwatch.observer/filing/0001477932-26-003126.json","markdown":"https://secwatch.observer/filing/0001477932-26-003126.md","text":"https://secwatch.observer/filing/0001477932-26-003126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793226003126/0001477932-26-003126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793226003126/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:46:38.860348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb61ecb1353d43c259eb1ec6460dfa0dbc8329da","claim":"VOLITIONRX LTD reported the first quarter 2026 results: revenue $1.0 million.","evidence_excerpt":"pillars; our laser focus is on executing licensing agreements and we will update you as they progress.” 1 Financial Highlights · Revenue for the first quarter was approximately $1.0 million, compared to $0.2 million for the same period in 2025. · Operating loss was down 3% for the quarter versus the comparable quarter in 2025. · Net cash used in operating activities","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793226003126/0001477932-26-003126-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter 2026"},{"label":"Revenue","value":"$1.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}